Melissa J. El Menaouar

Senior Counsel


Melissa Jeddeloh El Menaouar, Ph.D., is a senior counsel and intellectual property lawyer with Foley & Lardner LLP. She is a member of the Chemical, Biotechnology & Pharmaceutical Practice.

Dr. El Menaouar’s practice extends to all aspects of patent procurement, non-infringement, freedom to operate and invalidity opinions, due diligence, licensing and IP portfolio management in the chemical patent area including pharmaceuticals, nanotechnology, peptides, proteins, organic and enzymatic synthetic methods, catalysts, electrochemicals, batteries, composites, adhesives and polymers, paints and coatings, and medical devices.

In 2012, Dr. El Menaouar served as a summer associate and later as a part-time student associate with Foley. She also worked as a summer judicial clerk for Judge William M. Conley, U.S. District Court, Western District of Wisconsin. Prior to beginning her legal career, Dr. El Menaouar gained extensive academic and research experience at institutions such as the University of Wisconsin; University of California, Davis; and the University of Northern Iowa.


Dr. El Menaouar earned her law degree from the University of Wisconsin Law School (J.D., cum laude, 2013). She has a Ph.D. in organic chemistry from the University of California, Davis (2007), and her B.A. in chemistry and biology from the University of Northern Iowa (cum laude, 2003).


Dr. El Menaouar is admitted to practice in Wisconsin and before the U.S. Patent and Trademark Office.


  • Co-author, “PTAB Puts Method Of Treatment Patents Under The 101 Knife.” PharmaPatents, February 28, 2017
  • Co-author, "A Library of 3-Aryl-4,5-dihydroisoxazole-5-carboxamides." Journal of Combinatorial Chemistry, 9(6), 1041-1045
  • Co-author, "Identification of 2-nonynoic acid, a cosmetic component, as potential trigger of primary biliary cirrhosis." Journal of Autoimmunity, 27(1), 7-16
  • Co-author, "Aminodeoxychorismate Synthase Inhibitors from One-Bead One-Compound Combinatorial Libraries: 'Staged' Inhibitor Design." Journal of Medicinal Chemistry, 49(25), 7413-7426


PTAB Cannot Invalidate Challenged Claims for Indefiniteness in an IPR
18 February 2020
PTAB Trial Insights
15th Annual IP Conference
04 October 2019
Chicago, IL